15 results about "Digoxin" patented technology

The application provides a quantum dot microsphere fluorescent immunochromatography test paper for combined detection of ASFV antibodies and nucleic acids and an application thereof, and belongs to the technical field of veterinary biological diagnosis products. The quantum dot microsphere fluorescent immunochromatography test paper for combined detection of ASFV antibodies and nucleic acids comprises a base plate, on the base plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad are sequentially connected in a head-to-tail mode, from the combination pad to the water absorption pad, the nitrocellulose membrane is sequentially provided with an antibody detection line, a nucleic acid detection line and a quality control line, the antibody detection line is coated with a goat anti-pig IgG-Fc antibody, the nucleic acid detection line is coated with streptavidin, and the quality control line is coated with a rabbit anti-sheep IgG antibody; the combination pad is coated with a quantum dot microsphere labeled recombinant protein P22 and a quantum dot microsphere labeled sheep anti-digoxin antibody. The test paper can rapidly, highly specifically and highly sensitively detect ASFV antibodies and nucleic acids.

The invention discloses a digoxin drug concentration detection method, which comprises: S1, determining a to-be-detected drug, and carrying out working curve preparation on a detection object, the to-be-detected drug being digoxin; s2, taking out the to-be-detected sample, the calibration product, the quality control product and the internal standard extraction liquid, placing at room temperature, and uniformly mixing; s3, respectively taking a to-be-detected sample, a calibration product, a quality control product and a blank sample, putting into an EP tube, adding the internal standard intermediate solution, adding methanol, uniformly mixing by vortex, and centrifuging; s4, putting the supernate into a 96-well plate, adding ultrapure water, and putting the 96-well plate on a microwell plate oscillator for shaking; and S5, centrifuging in a multi-tube rack automatic balancing centrifuge, detecting and verifying by using liquid chromatogram-tandem mass spectrum, and collecting a mass spectrum signal. According to the present invention, the high performance liquid chromatography separation and the mass spectrometry are combined, such that the complex background interference in the blood sample is overcome, the cost performance is improved, and the high sensitivity, the high accuracy and the convenient detection can be achieved for the digoxin sample with the low in-vivo concentration.

The invention provides a dilated cardiomyopathy child death risk prediction method, system and device, and relates to the technical field of medical prediction models.The method comprises the steps that clinical data of a target dilated cardiomyopathy child patient are obtained and input into a pre-constructed nomogram prediction model, and death risk prediction results of the target dilated cardiomyopathy child patient at multiple time points in the future are output; the nomogram prediction model is constructed through independent prediction factors, the amino-terminal brain natriuretic peptide precursor level, the gender and the digoxin use condition which are determined through single-factor and multi-factor Cox regression analysis. According to the method, the nomogram prediction model is constructed by integrating the key clinical variables, accurate prediction and individualized treatment guidance of the dilated cardiomyopathy death risk of children are achieved, and the accuracy of clinical decision and the prognosis management effect are effectively improved.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

The invention relates to a digoxin immunodetection reagent as well as a preparation method and a detection method thereof, in particular to a digoxin chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the digoxin chemiluminescence immunodetection reagent comprises an anti-digoxin specific antibody and an indicating reagent for detecting an anti-digoxin specific antibody-digoxin conjugate, the anti-digoxin specific antibody is obtained by immunizing animals with digoxin immunogen. The digoxin immunogen has the beneficial effects that the digoxin immunogen has strong specificity and high immunogenicity, and the prepared anti-digoxin specific antibody has strong specificity and high titer; the chemiluminescence immunoassay reagent containing the anti-digoxin specific antibody can conveniently, quickly and accurately determine the content of digoxin in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay analyzer, realizes high-flux quick determination of digoxin, and is high in accuracy, strong in specificity and high in sensitivity. And the accuracy and the detection efficiency are greatly improved.

This invention belongs to the pharmaceutical field, specifically relating to the application of the combination of digetuxine and Lactobacillus reuteri in the preparation of an anti-amputation carcinoma drug. Through in vitro MTT assays of antitumor activity, this invention found that the combination of the cardiac glycoside drug digetuxine and the probiotic Lactobacillus reuteri can inhibit the proliferation of ampullary cancer cells and has a good inhibitory effect on ampullary carcinoma xenograft models. Furthermore, this combination alleviates the intestinal toxicity of digetuxine, and its therapeutic effect is superior to that of the commonly used clinical drug 5-fluorouracil, showing promising application prospects.

The invention discloses an application of Digoxin in preparation of a medicine for treating and / or preventing tumors. It is found for the first time that Digoxin can enhance the esophageal cancer radiotherapy sensitivity. Digoxin is a medicine which is approved by FDA, small in toxic and side effects and moderate in price, can be prepared into capsules for oral administration, and is used for radiotherapy sensitization of esophageal cancer and inhibition of growth of esophageal cancer.

The application provides a digoxin microtablet and a preparation method thereof. The digoxin microtablet prepared by the application contains 5-100 micrograms of digoxin per tablet, which can meet the dosage requirements of patients of different ages, realize precise dosage administration, and reduce the risk of drug overdose in clinical application. The digoxin microtablet provided by the application can solve the problem that infants and children have difficulty in swallowing the medicine, thereby improving the medication compliance of infants and children. Compared with conventional tablets, the microtablet has a smaller volume. The digoxin microtablet provided by the application is prepared by optimizing the prescription and process, preparing a digoxin compound by a spray drying and hot melt extrusion technology, obtaining a solid dispersion, and having better content uniformity and dissolution rate, and significantly improving the bioavailability.

This invention relates to the field of diclofenac preparation technology and discloses a method for preparing high-purity diclofenac, comprising the following steps: synthesis of BOC-D-phenylalanine-D-phenylalanine-D-leucine-N'-BOC-D-lysine; synthesis of BOC-D-phenylalanine-D-phenylalanine-D-leucine-N'-BOC-D-lysine-4-(Trt-amino)piperidine-4-carboxylic acid ethyl ester; synthesis of D-phenylalanine-D-phenylalanine-D-leucine-D-lysine-4-aminopiperidine-4-carboxylic acid ethyl ester; and synthesis of diclofenac. The key intermediates in the synthesis process of this invention can be obtained by precipitation or recrystallization, without the need for purification using chromatography columns or HPLC, offering advantages such as convenient operation and low cost, and ultimately producing high-purity diclofenac.

1. The name of the design product: packaging box (digoxin injection). 2. The use of the design product: the design product is used for packaging medicines. 3. The design points of the design product: the pattern of the product. 4. The picture or photo that best indicates the design points: front view.

This invention relates to the field of biology, and particularly to a ligand-coupled microsphere for measuring inverse-locking levels, its preparation method, and a method for measuring inverse-locking levels. The ligand-coupled microsphere comprises a ligand coupled with a first label, a DNA fragment, and a polystyrene microsphere. A second label is coupled to one end of the DNA fragment, and the second label specifically binds to the first label. Digoxigenin is coupled to the other end of the DNA fragment. An anti-digoxigenin antibody is coupled to the surface of the polystyrene microsphere, and the polystyrene microsphere is linked to the DNA fragment via the anti-digoxigenin antibody and digoxigenin. The measurement method of this invention can measure different receptor-ligand interactions and enables its application in commercial instruments, forming a more universal inverse-locking measurement method. This allows inverse-locking measurements to be applied in more situations, providing theoretical support for the engineering modification of various receptors such as TCR, and providing data support for clinical applications.

The invention relates to an oral pharmaceutical composition of diillain, which comprises diillain, a delivery agent, an auxiliary agent and an optional pharmaceutically acceptable inactive component, and can have good bioavailability and reduced variability of drug effectiveness.

The invention belongs to the field of quantitative cell incubation liquid drug concentration analysis, and particularly discloses a method for simultaneously detecting atenolol and digoxin in a cell incubation liquid. According to the method, the concentrations of atenolol and digoxin in the Hanke equilibrium salt buffer solution co-incubated with the cells can be accurately quantified at the same time through specific sample treatment and liquid chromatography and mass spectrometry conditions, the sensitivity is high, the detection limit is low, the normal excretion and transmembrane transport functions of Caco-2 cells in the research process are investigated, and the method has application and popularization value.

The present invention relates to humanized antibodies having good binding ability to digoxigenin and uses thereof. When an antibody or antigen-binding fragment thereof specifically recognizing digoxigenin according to one aspect of the present invention is used, the concentration of the drug in the body is adjusted as needed through a complex (DOligobody) containing the same, or the concentration of the drug in vivo It is expected that the half-life can be increased.